C-Jun N-Terminal Kinase Signaling Inhibitors Under Development

Overview

Journal Toxicol Res

Specialty Toxicology

Date 2020 Feb 11

PMID 32038782

Citations 1

Authors

Sun-Young Han

Affiliations

Soon will be listed here.

Abstract

Targeting protein kinases has been active area in drug discovery. The c-Jun N-terminal kinases (JNKs) have also been target for development of novel therapy in various diseases, since the roles of JNK signaling in pathological conditions were revealed in studies using -deficient mice. Small molecule inhibitors and peptide inhibitors are identified for therapeutic intervention of JNK signaling pathway. SP-600125, an anthrapyrazole small molecule inhibitor for JNK with high potency and selectivity has been widely used for dissecting JNK signaling pathway. CC-401 is the first JNK inhibitor that went into clinical trial for inflammation and leukemia. Inhibitor for mixed lineage kinase (MLK), CEP-1347 also negatively regulates JNK signaling, and tried for potential use in Parkinson's disease. Cell-permeable peptide inhibitor D-JNKI-1 is being developed for the treatment of hearing loss. The current status of these JNK inhibitors and safety issue is discussed in the minireview.

Citing Articles

c-Jun N-terminal kinase signaling in aging.

Li Y, You L, Nepovimova E, Adam V, Heger Z, Jomova K Front Aging Neurosci. 2024; 16:1453710.

PMID: 39267721 PMC: 11390425. DOI: 10.3389/fnagi.2024.1453710.

References

Kyriakis J, Avruch J . pp54 microtubule-associated protein 2 kinase. A novel serine/threonine protein kinase regulated by phosphorylation and stimulated by poly-L-lysine. J Biol Chem. 1990; 265(28):17355-63. View

Harper S, LoGrasso P . Signalling for survival and death in neurones: the role of stress-activated kinases, JNK and p38. Cell Signal. 2001; 13(5):299-310. DOI: 10.1016/s0898-6568(01)00148-6. View

Langston J . The etiology of Parkinson's disease with emphasis on the MPTP story. Neurology. 1996; 47(6 Suppl 3):S153-60. DOI: 10.1212/wnl.47.6_suppl_3.153s. View

Favata M, Horiuchi K, Manos E, Daulerio A, Stradley D, Feeser W . Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem. 1998; 273(29):18623-32. DOI: 10.1074/jbc.273.29.18623. View

Bennett B, Sasaki D, Murray B, OLeary E, Sakata S, Xu W . SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A. 2001; 98(24):13681-6. PMC: 61101. DOI: 10.1073/pnas.251194298. View

Barr R, Bogoyevitch M . The c-Jun N-terminal protein kinase family of mitogen-activated protein kinases (JNK MAPKs). Int J Biochem Cell Biol. 2001; 33(11):1047-63. DOI: 10.1016/s1357-2725(01)00093-0. View

Borsello T, Clarke P, Hirt L, Vercelli A, Repici M, Schorderet D . A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat Med. 2003; 9(9):1180-6. DOI: 10.1038/nm911. View

Ahlskog J . I can't get no satisfaction: still no neuroprotection for Parkinson disease. Neurology. 2007; 69(15):1476-7. DOI: 10.1212/01.wnl.0000277645.60799.0e. View

Manning A, Davis R . Targeting JNK for therapeutic benefit: from junk to gold?. Nat Rev Drug Discov. 2003; 2(7):554-65. DOI: 10.1038/nrd1132. View

10.

Wang J, Van De Water T, Bonny C, de Ribaupierre F, Puel J, Zine A . A peptide inhibitor of c-Jun N-terminal kinase protects against both aminoglycoside and acoustic trauma-induced auditory hair cell death and hearing loss. J Neurosci. 2003; 23(24):8596-607. PMC: 6740364. View

11.

. The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD. Neurology. 2004; 62(2):330-2. DOI: 10.1212/01.wnl.0000103882.56507.20. View

12.

Bonny C, Oberson A, Negri S, Sauser C, Schorderet D . Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. Diabetes. 2001; 50(1):77-82. DOI: 10.2337/diabetes.50.1.77. View

13.

Uehara T, Xi Peng X, Bennett B, Satoh Y, Friedman G, Currin R . c-Jun N-terminal kinase mediates hepatic injury after rat liver transplantation. Transplantation. 2004; 78(3):324-32. DOI: 10.1097/01.tp.0000128859.42696.28. View

14.

Manning G, Whyte D, Martinez R, Hunter T, Sudarsanam S . The protein kinase complement of the human genome. Science. 2002; 298(5600):1912-34. DOI: 10.1126/science.1075762. View

15.

Carboni S, Boschert U, Gaillard P, Gotteland J, Gillon J, Vitte P . AS601245, a c-Jun NH2-terminal kinase (JNK) inhibitor, reduces axon/dendrite damage and cognitive deficits after global cerebral ischaemia in gerbils. Br J Pharmacol. 2007; 153(1):157-63. PMC: 2199388. DOI: 10.1038/sj.bjp.0707574. View

16.

Furukawa M, Ebmeyer J, Pak K, Austin D, Melhus A, Webster N . Jun N-terminal protein kinase enhances middle ear mucosal proliferation during bacterial otitis media. Infect Immun. 2007; 75(5):2562-71. PMC: 1865762. DOI: 10.1128/IAI.01656-06. View

17.

Maroney A, Finn J, Connors T, Durkin J, Angeles T, Gessner G . Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family. J Biol Chem. 2001; 276(27):25302-8. DOI: 10.1074/jbc.M011601200. View

18.

Maroney A, Glicksman M, Basma A, Walton K, KNIGHT Jr E, Murphy C . Motoneuron apoptosis is blocked by CEP-1347 (KT 7515), a novel inhibitor of the JNK signaling pathway. J Neurosci. 1998; 18(1):104-11. PMC: 6793399. View

19.

Bain J, McLauchlan H, Elliott M, Cohen P . The specificities of protein kinase inhibitors: an update. Biochem J. 2003; 371(Pt 1):199-204. PMC: 1223271. DOI: 10.1042/BJ20021535. View

20.

Waldmeier P, Bozyczko-Coyne D, Williams M, Vaught J . Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases. Biochem Pharmacol. 2006; 72(10):1197-206. DOI: 10.1016/j.bcp.2006.06.031. View